This company operates in a sweet spot of compliance as a non SEC reporting company. No need for most reports yet the SEC will arm these scams with billions of shares of free trading stock with the reg A offering. Not to blame only the SEC and OTC for the malfeasance, the information available was enough to know that this was a share selling scheme. No accountability it would seem and no requirement for transparency as if investors don't stand to lose a bundle on schemes like this.
Where else can you simply change the date for share count updates hiding the dilution which was worse than not updating at all. Now the process of changing transfer agents is great for not revealing the ongoing dilution. Shareholders here will likely get slammed with another huge share count increase only revealed by the next quarterly report. Now we are seeing what the end game will look like here with a deal to unload this unprofitable business while rewarding Mexedia shareholders. The Raadr shareholders will get split down to nothing before the share swap. Other stinky pink OTC companies should be taking notes because the OTC gives these scams plenty of room to operate and the tactics are endless.
Market Data 
Markets 
AI
